Skip to search boxSkip to navigationSkip to main content

LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: Data from the Almenara Lupus Cohort

Research Output:
Contribution to journal
Article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Article number

e000616

Journal (Volume, Issue Number)

Lupus Science and Medicine (Volume 9, Issue 1)

Publication milestones

  • Published - 22/02/2022

Publication status

Published - 22/02/2022

Publication IDs

  • Scopus: 85125697472

Abstract

Objective To determine if achieving lupus low disease activity state (LLDAS) or remission prevents damage accrual in a primarily Mestizo population. Methods Patients with SLE from a single-centre cohort with at least two visits occurring every 6 months were included. The definitions used were the following: for remission, the 2021 Definition Of Remission In SLE; and for LLDAS, the Asia Pacific Lupus Collaboration. Damage accrual was ascertained with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Univariable and three multivariable interval-censored survival regression models were done: (1) remission versus not on remission; (2) LLDAS/remission versus active; and (3) remission and LLDAS (not on remission) versus active. Three similar multivariable models were also examined considering the duration on each state. Possible confounders included in these analyses were gender, age at diagnosis, socioeconomic status, educational level, disease duration, antimalarial use and SDI at baseline. Results Two hundred and eighty-one patients were included. Eighty-three patients (29.5%) showed increased SDI during the follow-up. In the analyses of remission, being on remission predicted a lower probability of damage (HR=0.456; 95% CI 0.256 to 0.826; p=0.010). In the analyses of LLDAS/remission, being on LLDAS/remission predicted a lower damage (HR=0.503; 95% CI 0.260 to 0.975; p=0.042). When both states were considered, remission but not LLDAS (not on remission) predicted a lower probability of damage (HR=0.423; 95% CI 0.212 to 0.846; p=0.015 and HR=0.878; 95% CI 0.369 to 2.087; p=0.768, respectively). When the duration of these states was taken into account, remission, LLDAS/remission and LLDAS not on remission were associated with a lower probability of damage accrual. Conclusions LLDAS and/or remission were associated with a lower probability of damage accrual.

Funding Details

Funding These analyses were done as part of a research grant from Janssen. Additionally the Almenara Lupus Cohort was partially supported by institutional grants from EsSalud (1483-GCGP-ESSALUD-2013, 1733-GCGP-ESSALUD-2014 and 2015 Kaelin Prize 04-IETSI-ESALUD-2016), Pan American League of Associations for Rheumatology (PANLAR) (2015 PANLAR Prize and 2018 H Ralph Schumacher MD/JCR/PANLAR Prize), and Fundación Instituto Hipólito Unanue. Competing interests MFU-G has grant support from Janssen and Pfizer. RVG-C has grant support from Pfizer. CR-S and VRP-Q have grant support from Janssen. JL, FZ and CSK are employees of Janssen Scientific Affairs. All other authors declare no other conflicts of interest.
FundersFunding numbers
EsSalud
04-IETSI-ESALUD-2016, 1733-GCGP-ESSALUD-2014, 1483-GCGP-ESSALUD-2013
Fundación Instituto Hipólito Unanue
-
Pan American League of Associations for Rheumatology
-
Pfizer
-
Janssen Pharmaceuticals
-

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Captures
16
Mentions
2
Citations
20
Social media
16